{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T01:43:08Z","timestamp":1789954988970,"version":"4.0.1"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,1,3]],"date-time":"2019-01-03T00:00:00Z","timestamp":1546473600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Familial Cancer"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1007\/s10689-018-00118-0","type":"journal-article","created":{"date-parts":[[2019,1,3]],"date-time":"2019-01-03T05:38:49Z","timestamp":1546493929000},"page":"273-280","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["TP53 germline mutation testing in early-onset breast cancer: findings from a nationwide cohort"],"prefix":"10.1007","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3181-5942","authenticated-orcid":false,"given":"J. J.","family":"Bakhuizen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F. B.","family":"Hogervorst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. E.","family":"Velthuizen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. W.","family":"Ruijs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"van Engelen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. A.","family":"van Os","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. J.","family":"Gille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Coll\u00e9e","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. M.","family":"van den Ouweland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. J.","family":"van Asperen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. M.","family":"Kets","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. R.","family":"Mensenkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. M.","family":"Leter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. J.","family":"Blok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. M.","family":"de Jong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. G.","family":"Ausems","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,1,3]]},"reference":[{"key":"118_CR1","unstructured":"Netherlands Comprehensive Cancer Organisation (IKNL) (2016) Dutch cancer Figs. 2016 [Internet]. http:\/\/www.cijfersoverkanker.nl\/ . Accessed May 21 2018"},{"key":"118_CR2","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1146\/annurev.genom.9.081307.164339","volume":"9","author":"C Turnbull","year":"2008","unstructured":"Turnbull C, Rahman N (2008) Genetic predisposition to breast cancer: past, present, and future. Annu Rev Genomics Hum Genet 9:321\u2013345","journal-title":"Annu Rev Genomics Hum Genet"},{"issue":"13","key":"118_CR3","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1200\/JCO.2015.65.0747","volume":"34","author":"N Tung","year":"2016","unstructured":"Tung N, Lin NU, Kidd J et al (2016) Frequency of germline mutations in 25 cancer susceptibility genes in a sequential series of patients with breast cancer. J Clin Oncol 34(13):1460\u20131468","journal-title":"J Clin Oncol"},{"issue":"6","key":"118_CR4","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1093\/oxfordjournals.aje.a115616","volume":"131","author":"EB Claus","year":"1990","unstructured":"Claus EB, Risch NJ, Thompson D (1990) Age at onset as an indicator of familial risk of breast cancer. Am J Epidemiol 131(6):961\u2013972","journal-title":"Am J Epidemiol"},{"key":"118_CR5","unstructured":"NABON (2017) Breast Cancer, Dutch Guideline [Internet]. http:\/\/www.oncoline.nl\/borstkanker . Accessed May 25 2018"},{"key":"118_CR6","unstructured":"National Comprehensive Cancer Network (2018) NCCN Clinical Practice Guidelines in Oncology: genetic\/familial high risk assessment: breast and ovarian (Version 2.2019) [internet]. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/genetics_screening.pdf (registration required). Accessed 7 Nov 2018"},{"key":"118_CR7","first-page":"A8910","volume":"159","author":"MA Adank","year":"2015","unstructured":"Adank MA, Hes FJ, van Zelst-Stams WAG et al (2015) CHEK2-mutation in Dutch breast cancer families: expanding genetic testing for breast cancer (in Dutch). Ned Tijdschr Geneeskd 159:A8910","journal-title":"Ned Tijdschr Geneeskd"},{"key":"118_CR8","volume-title":"GeneReviews [Internet]","author":"K Schneider","year":"1999","unstructured":"Schneider K, Zelley K, Nichols KE et al (1999) Li\u2013Fraumeni syndrome. In: Adam MP, Ardinger HH, Pagon RA, et al (eds) GeneReviews [Internet]. University of Washington, Seattle, WA"},{"issue":"8","key":"118_CR9","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1200\/JCO.2008.16.6959","volume":"27","author":"KD Gonzalez","year":"2009","unstructured":"Gonzalez KD, Noltner KA, Buzin CH et al (2009) Beyond Li Fraumeni Syndrome: clinical characteristics of families with p53 germline mutations. J Clin Oncol 27(8):1250\u20131256","journal-title":"J Clin Oncol"},{"issue":"23","key":"118_CR10","doi-asserted-by":"publisher","first-page":"3673","DOI":"10.1002\/cncr.30248","volume":"122","author":"PL Mai","year":"2016","unstructured":"Mai PL, Best AF, Peters JA et al (2016) Risks of first and subsequent cancers among TP53 mutation carriers in the National Cancer Institute Li\u2013Fraumeni syndrome cohort. Cancer 122(23):3673\u20133681","journal-title":"Cancer"},{"issue":"21","key":"118_CR11","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.1200\/JCO.2014.59.5728","volume":"33","author":"G Bougeard","year":"2015","unstructured":"Bougeard G, Renaux-Petel M, Flaman JM et al (2015) Revisiting Li\u2013Fraumeni Syndrome from TP53 mutation carriers. J Clin Oncol 33(21):2345\u20132352","journal-title":"J Clin Oncol"},{"issue":"18","key":"118_CR12","first-page":"5358","volume":"48","author":"FP Li","year":"1988","unstructured":"Li FP, Fraumeni JF Jr, Mulvihill JJ et al (1988) A cancer family syndrome in twenty-four kindreds. Cancer Res 48(18):5358\u20135362","journal-title":"Cancer Res"},{"issue":"5","key":"118_CR13","first-page":"1298","volume":"54","author":"JM Birch","year":"1994","unstructured":"Birch JM, Hartley AL, Tricker KJ et al (1994) Prevalence and diversity of constitutional mutations in the P53 gene among 21 Li\u2013Fraumeni families. Cancer Res 54(5):1298\u20131304","journal-title":"Cancer Res"},{"key":"118_CR14","first-page":"101","volume":"25","author":"RA Eeles","year":"1995","unstructured":"Eeles RA (1995) Germline mutations in the TP53 gene. Cancer Surv 25:101\u2013124","journal-title":"Cancer Surv"},{"issue":"1","key":"118_CR15","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1136\/jmg.38.1.43","volume":"38","author":"A Chompret","year":"2001","unstructured":"Chompret A, Abel A, Stoppa-Lyonnet D et al (2001) Sensitivity and predictive value of criteria for p53 germline mutation screening. J Med Genet 38(1):43\u201347","journal-title":"J Med Genet"},{"issue":"26","key":"118_CR16","doi-asserted-by":"publisher","first-page":"e108-9","DOI":"10.1200\/JCO.2009.22.7967","volume":"27","author":"J Tinat","year":"2009","unstructured":"Tinat J, Bougeard G, Baert-Desurmont S et al (2009) 2009 version of the Chompret criteria for Li Fraumeni syndrome. J Clin Oncol 27(26):e108-9","journal-title":"J Clin Oncol"},{"issue":"3","key":"118_CR17","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1136\/jmedgenet-2017-104976","volume":"55","author":"M Renaux-Petel","year":"2018","unstructured":"Renaux-Petel M, Charbonnier F, Thery JC et al (2018) Contribution of de novo and mosaic TP53 mutations to Li\u2013Fraumeni syndrome. J Med Genet 55(3):173\u2013180","journal-title":"J Med Genet"},{"issue":"8","key":"118_CR18","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1093\/jnci\/djy001","volume":"110","author":"HQ Rana","year":"2018","unstructured":"Rana HQ, Gelman R, LaDuca H et al (2018) Differences in TP53 mutation carrier phenotypes emerge from panel-based testing. J Natl Cancer Inst 110(8):863\u2013870","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"118_CR19","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1097\/CCO.0000000000000423","volume":"30","author":"A Amadou","year":"2018","unstructured":"Amadou A, Waddington Achatz MI, Hainaut P (2018) Revisiting tumor patterns and penetrance in germline TP53 mutation carriers: temporal phases of Li\u2013Fraumeni syndrome. Curr Opin Oncol 30(1):23\u201329","journal-title":"Curr Opin Oncol"},{"key":"118_CR20","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1002\/humu.23656","volume":"39","author":"C Fortuno","year":"2018","unstructured":"Fortuno C, James PA, Spurdle AB (2018) Current review of TP53 pathogenic germline variants in breast cancer patients outside Li\u2013Fraumeni syndrome. Hum Mutat 39:1764\u20131773","journal-title":"Hum Mutat"},{"issue":"9","key":"118_CR21","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1002\/humu.23035","volume":"37","author":"L Bouaoun","year":"2016","unstructured":"Bouaoun L, Sonkin D, Ardin M et al (2016) TP53 variations in human cancers: new lessons from the IARC TP53 database and genomics data. Hum Mutat 37(9):865\u2013876","journal-title":"Hum Mutat"},{"issue":"8","key":"118_CR22","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1016\/j.ejca.2005.11.032","volume":"42","author":"F Lalloo","year":"2006","unstructured":"Lalloo F, Varley J, Moran A et al (2006) BRCA1, BRCA2 and TP53 mutations in very early-onset breast cancer with associated risks to relatives. Eur J Cancer 42(8):1143\u20131150","journal-title":"Eur J Cancer"},{"issue":"12","key":"118_CR23","doi-asserted-by":"publisher","first-page":"4795","DOI":"10.1158\/0008-5472.CAN-09-0851","volume":"70","author":"J Mouchawar","year":"2010","unstructured":"Mouchawar J, Korch C, Byers T et al (2010) Population-based estimate of the contribution of TP53 mutations to subgroups of early-onset breast cancer: Australian Breast Cancer Family Study. Cancer Res 70(12):4795\u20134800","journal-title":"Cancer Res"},{"issue":"4","key":"118_CR24","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/s10689-012-9557-z","volume":"11","author":"JM McCuaig","year":"2012","unstructured":"McCuaig JM, Armel SR, Novokmet A et al (2012) Routine TP53 testing for breast cancer under age 30: ready for prime time? Fam Cancer 11(4):607\u2013613","journal-title":"Fam Cancer"},{"issue":"4","key":"118_CR25","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s10689-009-9287-z","volume":"8","author":"OM Ginsburg","year":"2009","unstructured":"Ginsburg OM, Akbari MR, Aziz Z et al (2009) The prevalence of germline TP53 mutations in women diagnosed with breast cancer before age 30. Fam Cancer 8(4):563\u2013567","journal-title":"Fam Cancer"},{"issue":"3","key":"118_CR26","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1093\/annonc\/mdv592","volume":"27","author":"DM Eccles","year":"2016","unstructured":"Eccles DM, Li N, Handwerker R et al (2016) Genetic testing in a cohort of young patients with HER2-amplified breast cancer. Ann Oncol 27(3):467\u2013473","journal-title":"Ann Oncol"},{"issue":"11","key":"118_CR27","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1136\/jmg.2010.078113","volume":"47","author":"JR Wilson","year":"2010","unstructured":"Wilson JR, Bateman AC, Hanson H et al (2010) A novel HER2-positive breast cancer phenotype arising from germline TP53 mutations. J Med Genet 47(11):771\u2013774","journal-title":"J Med Genet"},{"issue":"3","key":"118_CR28","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1007\/s10549-012-1993-9","volume":"133","author":"S Masciari","year":"2012","unstructured":"Masciari S, Dillon DA, Rath M et al (2012) Breast cancer phenotype in women with TP53 germline mutations: a Li\u2013Fraumeni syndrome consortium effort. Breast Cancer Res Treat 133(3):1125\u20131130","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"118_CR29","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1002\/cncr.26377","volume":"118","author":"A Melhem-Bertrandt","year":"2012","unstructured":"Melhem-Bertrandt A, Bojadzieva J, Ready KJ et al (2012) Early onset HER2-positive breast cancer is associated with germline TP53 mutations. Cancer 118(4):908\u2013913","journal-title":"Cancer"},{"key":"118_CR30","unstructured":"Netherlands Foundation for the Detection of Hereditary Tumours (STOET) and the Dutch Society of Clinical Genetics (VKGN) (2005) Guidelines for the diagnosis and prevention of hereditary cancer predisposition syndromes (in Dutch). Edition 2005"},{"key":"118_CR31","unstructured":"Netherlands Foundation for the Detection of Hereditary Tumours (STOET) and the Dutch Society of Clinical Genetics (VKGN) (2010) Guidelines for the diagnosis and prevention of hereditary cancer predisposition syndromes (in Dutch). Edition 2010"},{"key":"118_CR32","unstructured":"Netherlands Foundation for the Detection of Hereditary Tumours (STOET) and the Dutch Society of Clinical Genetics (VKGN) (2017) Guidelines for the diagnosis and prevention of hereditary cancer predisposition syndromes (in Dutch). Edition 2017"},{"key":"118_CR33","doi-asserted-by":"publisher","DOI":"10.1007\/s10689-018-0103-5","author":"JJ Bakhuizen","year":"2018","unstructured":"Bakhuizen JJ, Velthuizen ME, Stehouwer S et al (2018) Genetic counselling of young women with breast cancer for Li\u2013Fraumeni syndrome: a nationwide survey on the experiences and attitudes of genetics professionals. Fam Cancer. https:\/\/doi.org\/10.1007\/s10689-018-0103-5","journal-title":"Fam Cancer"},{"issue":"4","key":"118_CR34","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1038\/bjc.2013.805","volume":"110","author":"MR Wevers","year":"2014","unstructured":"Wevers MR, Aaronson NK, Verhoef S et al (2014) Impact of rapid genetic counselling and testing on the decision to undergo immediate or delayed prophylactic mastectomy in newly diagnosed breast cancer patients: findings from a randomised controlled trial. Br J Cancer 110(4):1081\u20131087","journal-title":"Br J Cancer"},{"issue":"5","key":"118_CR35","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards S, Aziz N, Bale S et al (2015) Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 17(5):405\u2013424","journal-title":"Genet Med"},{"issue":"2","key":"118_CR36","doi-asserted-by":"publisher","first-page":"R66","DOI":"10.1186\/bcr3172","volume":"14","author":"DS Lee","year":"2012","unstructured":"Lee DS, Yoon SY, Looi LM et al (2012) Comparable frequency of BRCA1, BRCA2 and TP53 germline mutations in a multi-ethnic Asian cohort suggests TP53 screening should be offered together with BRCA1\/2 screening to early-onset breast cancer patients. Breast Cancer Res 14(2):R66. https:\/\/doi.org\/10.1186\/bcr3172","journal-title":"Breast Cancer Res"},{"issue":"3","key":"118_CR37","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1111\/j.1399-0004.2008.01133.x","volume":"75","author":"P Ang","year":"2009","unstructured":"Ang P, Lim IH, Yong RY, Lee AS (2009) A molecular approach for identifying individuals with Li\u2013Fraumeni syndrome who have a limited family history. Clin Genet 75(3):294\u2013297","journal-title":"Clin Genet"},{"issue":"3","key":"118_CR38","doi-asserted-by":"publisher","first-page":"e57581","DOI":"10.1371\/journal.pone.0057581","volume":"8","author":"DM Carraro","year":"2013","unstructured":"Carraro DM, Koike Folgueira MA, Garcia Lisboa BC et al (2013) Comprehensive analysis of BRCA1, BRCA2 and TP53 germline mutation and tumor characterization: a portrait of early-onset breast cancer in Brazil. PLoS ONE 8(3):e57581","journal-title":"PLoS ONE"},{"issue":"1","key":"118_CR39","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s10549-012-2375-z","volume":"139","author":"MG Rath","year":"2013","unstructured":"Rath MG, Masciari S, Gelman R et al (2013) Prevalence of germline TP53 mutations in HER2+ breast cancer patients. Breast Cancer Res Treat 139(1):193\u2013198","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"118_CR40","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s10689-017-0002-1","volume":"17","author":"R O\u2019Shea","year":"2017","unstructured":"O\u2019Shea R, Clarke R, Berkley E et al (2017) Next generation sequencing is informing phenotype: a TP53 example. Fam Cancer 17(1):123\u2013128","journal-title":"Fam Cancer"},{"issue":"2","key":"118_CR41","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s10549-017-4531-y","volume":"167","author":"K Schon","year":"2018","unstructured":"Schon K, Tischkowitz M (2018) Clinical implications of germline mutations in breast cancer: TP53. Breast Cancer Res Treat 167(2):417\u2013423","journal-title":"Breast Cancer Res Treat"},{"key":"118_CR42","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/1748-717X-5-104","volume":"5","author":"S Heymann","year":"2010","unstructured":"Heymann S, Delaloge S, Rahal A et al (2010) Radio-induced malignancies after breast cancer postoperative radiotherapy in patients with Li\u2013Fraumeni syndrome. Radiat Oncol 5:104","journal-title":"Radiat Oncol"},{"issue":"4","key":"118_CR43","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1007\/s10689-009-9265-5","volume":"8","author":"C Lammens","year":"2009","unstructured":"Lammens C, Bleiker E, Aaronson N et al (2009) Attitude towards pre-implantation genetic diagnosis for hereditary cancer. Fam Cancer 8(4):457\u2013464","journal-title":"Fam Cancer"},{"key":"118_CR44","unstructured":"PGD Netherlands (2017) Annual report 2017 [Internet]. https:\/\/www.pgdnederland.nl\/en\/annual-reports . Accessed 7 Nov 2018"},{"issue":"12","key":"118_CR45","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1001\/jamaoncol.2017.1968","volume":"3","author":"ML Ballinger","year":"2017","unstructured":"Ballinger ML, Best A, Mai PL et al (2017) Baseline surveillance in Li\u2013Fraumeni Syndrome using whole-body magnetic sesonance imaging: a meta-analysis. JAMA Oncol 3(12):1634\u20131639","journal-title":"JAMA Oncol"},{"issue":"6","key":"118_CR46","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/S1470-2045(11)70119-X","volume":"12","author":"A Villani","year":"2011","unstructured":"Villani A, Tabori U, Schiffman J et al (2011) Biochemical and imaging surveillance in germline TP53 mutation carriers with Li\u2013Fraumeni syndrome: a prospective observational study. Lancet Oncol 12(6):559\u2013567","journal-title":"Lancet Oncol"},{"issue":"9","key":"118_CR47","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1016\/S1470-2045(16)30249-2","volume":"17","author":"A Villani","year":"2016","unstructured":"Villani A, Shore A, Wasserman JD et al (2016) Biochemical and imaging surveillance in germline TP53 mutation carriers with Li\u2013Fraumeni syndrome: 11 year follow-up of a prospective observational study. Lancet Oncol 17(9):1295\u20131305","journal-title":"Lancet Oncol"},{"issue":"5","key":"118_CR48","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1038\/nrclinonc.2014.41","volume":"11","author":"KA McBride","year":"2014","unstructured":"McBride KA, Ballinger ML, Killick E et al (2014) Li\u2013Fraumeni syndrome: cancer risk assessment and clinical management. Nat Rev Clin Oncol 11(5):260\u2013271","journal-title":"Nat Rev Clin Oncol"},{"issue":"12","key":"118_CR49","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1001\/jamaoncol.2017.1346","volume":"3","author":"MWG Ruijs","year":"2017","unstructured":"Ruijs MWG, Loo CE, van Buchem CAJM, Bleiker EMA, Sonke GS (2017) Surveillance of Dutch patients with Li\u2013Fraumeni syndrome: the LiFe-Guard Study. JAMA Oncol 3(12):1733\u20131734","journal-title":"JAMA Oncol"},{"issue":"8","key":"118_CR50","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1002\/pon.1352","volume":"17","author":"SK Peterson","year":"2008","unstructured":"Peterson SK, Pentz RD, Marani SK et al (2008) Psychological functioning in persons considering genetic counseling and testing for Li\u2013Fraumeni syndrome. Psychooncology 17(8):783\u2013789","journal-title":"Psychooncology"},{"issue":"18","key":"118_CR51","doi-asserted-by":"publisher","first-page":"3008","DOI":"10.1200\/JCO.2009.27.2112","volume":"28","author":"CR Lammens","year":"2010","unstructured":"Lammens CR, Aaronson NK, Wagner A et al (2010) Genetic testing in Li\u2013Fraumeni syndrome: uptake and psychosocial consequences. J Clin Oncol 28(18):3008\u20133014","journal-title":"J Clin Oncol"},{"issue":"6","key":"118_CR52","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1002\/pon.1951","volume":"20","author":"CR Lammens","year":"2011","unstructured":"Lammens CR, Bleiker EM, Verhoef S et al (2011) Distress in partners of individuals diagnosed with or at high risk of developing tumors due to rare hereditary cancer syndromes. Psychooncology 20(6):631\u2013638","journal-title":"Psychooncology"},{"issue":"3","key":"118_CR53","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s10689-017-0020-z","volume":"17","author":"J Azzollini","year":"2018","unstructured":"Azzollini J, Mariani M, Peissel B, Manoukian S (2018) Increased access to TP53 analysis through breast cancer multi-gene panels: clinical considerations. Fam Cancer 17(3):317\u2013319","journal-title":"Fam Cancer"},{"issue":"8","key":"118_CR54","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1038\/gim.2017.250","volume":"20","author":"SP MacFarland","year":"2018","unstructured":"MacFarland SP, Maxwell KN (2018) The differential diagnosis of a TP53 genetic testing result. Genet Med 20(8):806\u2013808","journal-title":"Genet Med"}],"container-title":["Familial Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10689-018-00118-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10689-018-00118-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10689-018-00118-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,21]],"date-time":"2020-11-21T12:36:44Z","timestamp":1605962204000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10689-018-00118-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,3]]},"references-count":54,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["118"],"URL":"https:\/\/doi.org\/10.1007\/s10689-018-00118-0","relation":{},"ISSN":["1389-9600","1573-7292"],"issn-type":[{"value":"1389-9600","type":"print"},{"value":"1573-7292","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,3]]},"assertion":[{"value":"3 January 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The Medical Research Ethical Committee concluded that the Medical Research Human Subject Acts (WMO) does not apply.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}